MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Jun 26, 04:58 PM (EDT)
Price
$24.97
Change
+$0.08 (+0.32%)
Net Assets
71.32M

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Jun 25, 2025

CANC sees its Stochastic Oscillator ascending out of oversold territory

On June 25, 2025, the Stochastic Oscillator for CANC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 21 instances where the indicator left the oversold zone. In of the 21 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

CANC moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CANC crossed bullishly above the 50-day moving average on May 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 115 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 73 cases where CANC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CANC moved out of overbought territory on June 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CANC as a result. In of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 16 similar instances when the indicator turned negative. In of the 16 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CANC broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 42.61B. The market cap for tickers in the group ranges from 3.51M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 14%. For the same ETF, the average monthly price growth was 82%, and the average quarterly price growth was 64%. AUTL experienced the highest price growth at 13%, while SNDX experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was -23%. For the same stocks of the ETF, the average monthly volume growth was 5% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 54
SMR Rating: 81
Profit Risk Rating: 80
Seasonality Score: 36 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co